Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.
Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States.
Front Immunol. 2023 Mar 24;14:1135841. doi: 10.3389/fimmu.2023.1135841. eCollection 2023.
Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV vaccine development. However, the molecular antibody features important for broad neutralization are not known.
To identify B cell repertoire features associated with broad neutralization, we performed RNA sequencing of the B cell receptors (BCRs) of HCV E2-reactive B cells of HCV-infected individuals with either high or low plasma neutralizing breadth. We then produced a monoclonal antibody (mAb) expressed by pairing the most abundant heavy and light chains from public clonotypes identified among clearance, high neutralization subjects.
We found distinctive BCR features associated with broad neutralization of HCV, including long heavy chain complementarity determining region 3 (CDRH3) regions, specific VH gene usage, increased frequencies of somatic hypermutation, and particular VH gene mutations. Most intriguing, we identified many E2-reactive public BCR clonotypes (heavy and light chain clones with the same V and J-genes and identical CDR3 sequences) present only in subjects who produced highly neutralizing plasma. The majority of these public clonotypes were shared by two subjects who cleared infection. A mAb expressing the most abundant public heavy and light chains from these clearance, high neutralization subjects had features enriched in high neutralization clonotypes, such as increased somatic hypermutation frequency and usage of , and was cross-neutralizing.
Together, these results demonstrate distinct BCR repertoires associated with high plasma neutralizing capacity. Further characterization of the molecular features and function of these antibodies can inform HCV vaccine development.
针对丙型肝炎病毒 (HCV) 包膜糖蛋白 E2 的广泛中和抗体 (bNAb) 的早期发展与感染的自发清除有关,因此诱导 bNAb 是 HCV 疫苗开发的主要目标。然而,广泛中和所必需的分子抗体特征尚不清楚。
为了确定与广泛中和相关的 B 细胞受体 (BCR) 特征,我们对具有高或低血浆中和广度的 HCV 感染个体的 HCV E2 反应性 B 细胞的 BCR 进行了 RNA 测序。然后,我们通过配对从清除、高中和受试者中鉴定出的公共克隆型中最丰富的重链和轻链,产生了一种单克隆抗体 (mAb)。
我们发现了与 HCV 广泛中和相关的独特 BCR 特征,包括长重链互补决定区 3 (CDRH3) 区、特定的 VH 基因使用、体细胞高频突变频率增加以及特定的 VH 基因突变。最有趣的是,我们鉴定出许多仅存在于产生高度中和血浆的受试者中的 E2 反应性公共 BCR 克隆型(具有相同 V 和 J 基因和相同 CDR3 序列的重链和轻链克隆)。这些公共克隆型中的大多数都被两个清除感染的受试者共享。表达来自这些清除、高中和受试者的最丰富公共重链和轻链的 mAb 具有高中和克隆型中富集的特征,例如体细胞高频突变频率增加和使用,并且具有交叉中和作用。
这些结果共同表明与高血浆中和能力相关的独特 BCR 库。进一步表征这些抗体的分子特征和功能可以为 HCV 疫苗开发提供信息。